需要活的波萨达斯球孢子菌Δcps1孢子才能接种疫苗并提供持久免疫
研究在小鼠中探索波萨达斯球孢子菌Δcps1减毒株孢子的保护条件与免疫应答:只有活孢子接种才能抵抗致死性攻击,免疫至少持续6个月,并交叉保护粗球孢子菌;保护依赖CD4+细胞及IFN-γ的Th1应答。
要点
- 活Δcps1孢子接种是抵抗致死性攻击所必需,不同剂量与活力状态被比较。
- 活孢子接种产生持久免疫,至少持续6个月,并延长生存期至≥6个月。
- Δcps1疫苗株还保护小鼠抵抗粗球孢子菌,生存期≥6个月。
核心结论
- 活的Δcps1孢子接种是小鼠抵抗致死性波萨达斯球孢子菌攻击所必需,并可产生至少6个月的持久免疫和交叉保护。
研究设计与样本
- 小鼠接种不同剂量和不同活力状态的Δcps1孢子,随后用强毒波萨达斯球孢子菌攻击,按实验目的在不同终点处死。
- 采集接种小鼠组织用于体外免疫应答研究。
主要发现
- 只有活Δcps1孢子接种才能保护小鼠抵抗致死性攻击。
- 活孢子接种产生持久免疫,至少持续6个月,并延长生存期至≥6个月。
- Δcps1疫苗株还保护小鼠抵抗粗球孢子菌,生存期≥6个月。
- 攻击后前4天,接种小鼠感染肺组织的细胞因子显示IFN-γ显著增加,接种小鼠受刺激的CD4+脾细胞亦然。
- 转移CD4+细胞而非CD8+或B细胞可降低攻击后的真菌负荷。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coccidioidomycosis is a systemic fungal infection for which a vaccine has been sought for over fifty years. The avirulent Coccidioides posadasii strain, Δcps1, which is missing a 6 kb gene, showed significant protection in mice. These studies explore conditions of protection in mice and elucidate the immune response. Mice were vaccinated with different doses and viability states of Δcps1 spores, challenged with virulent C. posadasii, and sacrificed at various endpoints, dependent on experimental objectives. Tissues from vaccinated mice were harvested for in vitro elucidation of immune response. Vaccination with viable Δcps1 spores was required for protection from lethal challenge. Viable spore vaccination produced durable immunity, lasting at least 6 months, and prolonged survival (≥6 months). The C. posadasii vaccine strain also protected mice against C. immitis (survival ≥ 6 months). Cytokines from infected lungs of vaccinated mice in the first four days after Cp challenge showed significant increases of IFN-γ, as did stimulated CD4+ spleen cells from vaccinated mice. Transfer of CD4+ cells, but not CD8+ or B cells, reduced fungal burdens following challenge. IFN-γ from CD4+ cells in vaccinated mice indicates a Th1 response, which is critical for host control of coccidioidomycosis.
引用
- Shubitz LF, Powell DA, Trinh HT, et al. Viable spores of Coccidioides posadasii Δcps1 are required for vaccination and provide long lasting immunity. Vaccine. 2018. PMID: 29724507. doi:10.1016/j.vaccine.2018.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。